July 22, 2015 by Chain Drug Review and Chain Drug Review
biopharmaceutical industry, biosimilars, Chester "Chip" Davis, Craig Wheeler, generic drugs, Generic Pharmaceutical Association, GPhA, Ralph Neas
Featured Articles, Leading Headlines, Pharmacy, Supplier News
WASHINGTON — Chester “Chip” Davis has been named president and chief executive officer of the Generic Pharmaceutical Association (GPhA), taking over from Ralph Neas, who is stepping down. GPhA said Wednesday that Davis, previously executive vice president for advocacy and member relations at Pharmaceutical Research and Manufacturers of America (PhRMA), is slated to start in
April 27, 2015 by Geoff Walden and Chain Drug Review
Department of Health and Human Services, generic drug price increases, Generic Pharmaceutical Association, HHS, Medicaid, Ralph Neas, Rep. Elijah Cummings, Sen. Bernie Sanders
2015, Issue 04-27-2015, Leading Headlines, News, Pharmacy, Retail News
WASHINGTON — The federal government is looking into the effect of generic drug price increases on Medicaid. The Office of the Inspector General of the Department of Health and Human Services (HHS) will compare generic price increases between 2005 and 2014 to the inflation rate. The probe comes in response to questions raised about generics
February 16, 2015 by Mark Baumgartner and Chain Drug Review
Food and Drug Administration, Francis Collins, Generic Pharmaceutical Association, Margaret Hamburg, National Institutes of Health, Ralph Neas, Stephen Ostroff
2015, Issue 02-16-2015, News, Pharmacy
WASHINGTON — Dr. Margaret Hamburg, commissioner of the Food and Drug Administration, will step aside next month after nearly six years at the helm of the agency overseeing many of the nation’s most contentious public policy issues and products representing about 20% of every dollar spent by consumers. Hamburg, 59, said her decision to step
February 2, 2015 by John Schultz and Chain Drug Review
CEO, chief executive officer, Craig Wheeler, generic drug industry, Generic Pharmaceutical Association, GPhA, Hatch-Waxman Act, president, Ralph Neas
2015, Issue 02-02-2015, News, Pharmacy
WASHINGTON — Ralph Neas, president and chief executive officer of the Generic Pharmaceutical Association, has announced he will step down from his position in the fall. Neas has led GPhA since September 2011. During his remaining tenure, he will continue to serve as CEO until a successor is named and will work to ensure a
January 19, 2015 by John Schultz and Chain Drug Review
Affordable Prescription Drugs, biologics exclusivity, Centers for Medicare & Medicaid Services, drug costs, generic drug price spikes, generic drug use, generic drugs, Generic Pharmaceutical Association, GPhA, Medicare Part D, Medicare Payment Advisory Committee, MedPAC, Peter Welch, Ralph Neas, Sen. Bill Nelson, Sen. Susan Collins, Senate Special Committee on Aging, Steve Stivers
2015, Issue 01-19-2015, News, Pharmacy
WASHINGTON — Providing incentives to prescription drug plan sponsors that increase generic drug use is among recommendations that the Senate Special Committee on Aging unveiled last month in a bipartisan report that focuses on ways to increase the utilization of generics within the Medicare Part D program. The panel also heard about industry issues beyond
January 19, 2015 by John Schultz and Chain Drug Review
biosimilar, cancer treatment, Center for Drug Evaluation and Research, FDA, Food and Drug Administration, Generic Pharmaceutical Association, Janet Woodcock, Johnson & Johnson, Merck, Neupogen, Neupogen biosimilar, Ralph Neas, Remicade, rheumatoid arthritis drug, Sandoz, Zarzio
2015, Issue 01-19-2015, News, Pharmacy
WASHINGTON — A Food and Drug Administration panel has recommended that the agency approve what could become the country’s first biosimilar. The panel unanimously urged approval of Sandoz’s filgrastin (Neupogen), a cancer treatment. “This encouraging step forward means that it is very likely now only a question of when, rather than if, filgrastin will be available